Innovent Biologics and Sanegene Bio Reveal Findings on IBI3016

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Nov 10 2025

0mins

Clinical Study Announcement: Innovent Biologics and Sanegene Bio USA reported preliminary results from a Phase 1 clinical study of IBI3016, an experimental siRNA medicine targeting angiotensinogen mRNA, at the 2025 AHA scientific sessions.
Study Results: The study, presented by Dr. Fangfang Wang, showed that IBI3016 effectively suppresses AGT mRNA and provides preliminary evidence of antihypertensive efficacy after a single subcutaneous dose.
Potential Treatment: The Phase 1 data suggests the possibility of biannual subcutaneous dosing for hypertension treatment, indicating a promising new approach in managing the condition.
Next Steps: Development for the next phase of the clinical study is set to begin soon, indicating ongoing progress in the research of IBI3016.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.